Literature DB >> 24642682

Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies.

Jan A Burger1, Klaus Okkenhaug2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24642682      PMCID： PMC4536758          DOI： 10.1038/nrclinonc.2014.42

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

Review 1.  B cell receptor signaling in chronic lymphocytic leukemia.

Authors:  Jan A Burger; Nicholas Chiorazzi
Journal:  Trends Immunol       Date:  2013-08-05       Impact factor: 16.687

Review 2.  The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies.

Authors:  Jan A Burger; John G Gribben
Journal:  Semin Cancer Biol       Date:  2013-09-07       Impact factor: 15.707

3.  Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

Authors:  Richard R Furman; Jeff P Sharman; Steven E Coutre; Bruce D Cheson; John M Pagel; Peter Hillmen; Jacqueline C Barrientos; Andrew D Zelenetz; Thomas J Kipps; Ian Flinn; Paolo Ghia; Herbert Eradat; Thomas Ervin; Nicole Lamanna; Bertrand Coiffier; Andrew R Pettitt; Shuo Ma; Stephan Stilgenbauer; Paula Cramer; Maria Aiello; Dave M Johnson; Langdon L Miller; Daniel Li; Thomas M Jahn; Roger D Dansey; Michael Hallek; Susan M O'Brien
Journal:  N Engl J Med       Date:  2014-01-22       Impact factor: 91.245

4.  PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

Authors:  Ajay K Gopal; Brad S Kahl; Sven de Vos; Nina D Wagner-Johnston; Stephen J Schuster; Wojciech J Jurczak; Ian W Flinn; Christopher R Flowers; Peter Martin; Andreas Viardot; Kristie A Blum; Andre H Goy; Andrew J Davies; Pier Luigi Zinzani; Martin Dreyling; Dave Johnson; Langdon L Miller; Leanne Holes; Daniel Li; Roger D Dansey; Wayne R Godfrey; Gilles A Salles
Journal:  N Engl J Med       Date:  2014-01-22       Impact factor: 91.245

5.  The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.

Authors:  Julia Hoellenriegel; Sarah A Meadows; Mariela Sivina; William G Wierda; Hagop Kantarjian; Michael J Keating; Neill Giese; Susan O'Brien; Albert Yu; Langdon L Miller; Brian J Lannutti; Jan A Burger
Journal:  Blood       Date:  2011-07-29       Impact factor: 22.113

Review 6.  PI3K and cancer: lessons, challenges and opportunities.

Authors:  David A Fruman; Christian Rommel
Journal:  Nat Rev Drug Discov       Date:  2014-02       Impact factor: 84.694

7.  Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Authors:  Jonathan W Friedberg; Jeff Sharman; John Sweetenham; Patrick B Johnston; Julie M Vose; Ann Lacasce; Julia Schaefer-Cutillo; Sven De Vos; Rajni Sinha; John P Leonard; Larry D Cripe; Stephanie A Gregory; Michael P Sterba; Ann M Lowe; Ronald Levy; Margaret A Shipp
Journal:  Blood       Date:  2009-11-17       Impact factor: 22.113

8.  Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice.

Authors:  Klaus Okkenhaug; Antonio Bilancio; Géraldine Farjot; Helen Priddle; Sara Sancho; Emma Peskett; Wayne Pearce; Stephen E Meek; Ashreena Salpekar; Michael D Waterfield; Andrew J H Smith; Bart Vanhaesebroeck
Journal:  Science       Date:  2002-07-18       Impact factor: 47.728

9.  PI3 kinase signals BCR-dependent mature B cell survival.

Authors:  Lakshmi Srinivasan; Yoshiteru Sasaki; Dinis Pedro Calado; Baochun Zhang; Ji Hye Paik; Ronald A DePinho; Jeffrey L Kutok; John F Kearney; Kevin L Otipoby; Klaus Rajewsky
Journal:  Cell       Date:  2009-10-30       Impact factor: 41.582

10.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie A Blum; Barbara Grant; Jeff P Sharman; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Juthamas Sukbuntherng; Betty Y Chang; Fong Clow; Eric Hedrick; Joseph J Buggy; Danelle F James; Susan O'Brien
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245
  10 in total
  16 in total

Review 1.  Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia.

Authors:  Markus Müschen
Journal:  Blood       Date:  2015-04-15       Impact factor: 22.113

Review 2.  Chemokines, their receptors and human disease: the good, the bad and the itchy.

Authors:  Vanessa L Bryant; Charlotte A Slade
Journal:  Immunol Cell Biol       Date:  2015-04       Impact factor: 5.126

3.  PIK3CD promoted proliferation in diffuse large B cell lymphoma through upregulation of c-myc.

Authors:  Wenli Cui; Shutao Zheng; Xinxia Li; Yuqing Ma; Wei Sang; Ming Liu; Wei Zhang; Xiaoyan Zhou
Journal:  Tumour Biol       Date:  2016-07-22

Review 4.  PI3K Targeting in Non-solid Cancer.

Authors:  Hye Na Kim; Heather Ogana; Vanessa Sanchez; Cydney Nichols; Yong-Mi Kim
Journal:  Curr Top Microbiol Immunol       Date:  2022       Impact factor: 4.737

Review 5.  Big opportunities for small molecules in immuno-oncology.

Authors:  Jerry L Adams; James Smothers; Roopa Srinivasan; Axel Hoos
Journal:  Nat Rev Drug Discov       Date:  2015-07-31       Impact factor: 84.694

Review 6.  Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia in Patients with Comorbidities: New Agents, New Hope.

Authors:  Valentin Goede; Michael Hallek
Journal:  Drugs Aging       Date:  2015-11       Impact factor: 3.923

Review 7.  The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia.

Authors:  J Eswaran; P Sinclair; O Heidenreich; J Irving; L J Russell; A Hall; D P Calado; C J Harrison; J Vormoor
Journal:  Leukemia       Date:  2015-05-06       Impact factor: 11.528

8.  Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia.

Authors:  Huimin Geng; Christian Hurtz; Kyle B Lenz; Zhengshan Chen; Dirk Baumjohann; Sarah Thompson; Natalya A Goloviznina; Wei-Yi Chen; Jianya Huan; Dorian LaTocha; Erica Ballabio; Gang Xiao; Jae-Woong Lee; Anne Deucher; Zhongxia Qi; Eugene Park; Chuanxin Huang; Rahul Nahar; Soo-Mi Kweon; Seyedmehdi Shojaee; Lai N Chan; Jingwei Yu; Steven M Kornblau; Janetta J Bijl; B Hilda Ye; K Mark Ansel; Elisabeth Paietta; Ari Melnick; Stephen P Hunger; Peter Kurre; Jeffrey W Tyner; Mignon L Loh; Robert G Roeder; Brian J Druker; Jan A Burger; Thomas A Milne; Bill H Chang; Markus Müschen
Journal:  Cancer Cell       Date:  2015-03-09       Impact factor: 31.743

9.  New agents for the treatment of lymphoid leukemia and lymphoma: focus on recent FDA approvals.

Authors:  Andreea Lucia Stancu; Mitchell R Smith; Alexandru Almasan
Journal:  Discoveries (Craiova)       Date:  2014 Jan-Mar

10.  Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia.

Authors:  S Eldfors; H Kuusanmäki; M Kontro; M M Majumder; A Parsons; H Edgren; T Pemovska; O Kallioniemi; K Wennerberg; N Gökbuget; T Burmeister; K Porkka; C A Heckman
Journal:  Leukemia       Date:  2016-07-27       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.